Tenderwize
Retour à la recherche

Denosumab (60mg) Discount Agreement

Techniker Krankenkasse·Hamburg, Germany·Deadline Nov 29, 2027 · 460 days left·Open·Supplies
Inscrivez-vous pour sauvegarderOpen documents
Structured notice only
Titre original de l'avis

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 19 - Denosumab (Wirkstärke 60mg)

45/100

Score d'opportunité

Needs reviewMedium complexity
SuppliesOpen
Pourquoi ce score ?

Opportunité

45 / 100

Complexité

40 / 100

Facteurs de risque

Non-compliance with eligibility criteria (e.g., authorization status) could lead to contract invalidation. Self-declara...

No estimated value or volume provided; actual revenue from this agreement is uncertain. Low prescription volumes could...

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Moderate opportunity

Faits clés

  • Supplies contract
  • 1 lot
  • Duration until Nov 2027
  • Supply of Denosumab (strength 60mg) pharmaceutical products
  • Conclusion of discount agreements with TK and participating health insurances
Afficher le résumé complet

Open House discount agreement (Rabattvertrag) for Denosumab (strength 60mg) with the Techniker Krankenkasse (TK) and participating health insurances (HEK, hkk). The procedure is a non-competitive Open House with uniform conditions, no exclusivity, and maximum 17-month duration (1 July 2026 to 30 November 2027). All qualified pharmaceutical entrepreneurs can join at any time. No estimated value is provided.

Risques

Non-compliance with eligibility criteria (e.g., authorization status) could lead to contract invalidation. Self-declara...

No estimated value or volume provided; actual revenue from this agreement is uncertain. Low prescription volumes could...

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

  • Must be a pharmaceutical entrepreneur as per § 4 Abs. 18 AMG with valid authorization
  • Must have a registered seat in Germany, EU, or EEA

Administrative

  • Must provide self-declaration regarding authorization and reliability

Les exigences peuvent être incomplètes.

Acheteur

Localisation

Hamburg, DEU

Identifiant

992-80116-93

Activité

Health

Lots (1)

LOT-0001

Denosumab (60mg) Discount Agreement

Open House agreement for Denosumab 60mg discount contracts under § 130a Abs. 8 SGB V. Supply of pharmaceutical product with no exclusivity. Maximum 17 months from 1 July 2026 to 30 November 2027.

SuppliesEU fundedElectronic submission

Localisation

DE600, Germany

Durée

Jun 2026 - Nov 2027

Catégorie

Pharmaceutical products

Date limite

Deadline Nov 29, 2027

Détails de la procédure

Date de publication
25 May 2026
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
354637-2026

Documents (1)

Document de consultation 1

Appels d'offres similaires

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Belgium – Pharmaceutical products – Antimycotica

Aug 27

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3